US20040151751A1 - Calcium phosphate/sulphate-based bone implant composition - Google Patents
Calcium phosphate/sulphate-based bone implant composition Download PDFInfo
- Publication number
- US20040151751A1 US20040151751A1 US10/476,242 US47624204A US2004151751A1 US 20040151751 A1 US20040151751 A1 US 20040151751A1 US 47624204 A US47624204 A US 47624204A US 2004151751 A1 US2004151751 A1 US 2004151751A1
- Authority
- US
- United States
- Prior art keywords
- composition according
- calcium
- composition
- ions
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/427—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of other specific inorganic materials not covered by A61L27/422 or A61L27/425
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
- A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/112—Phosphorus-containing compounds, e.g. phosphates, phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- This invention concerns a bone implant composition, and a method of forming a bone graft.
- the bone graft material of preferred choice is autograft, i.e. the patients own bone, since this is totally biocompatible, is not subject to an immune response or disease transmission and has good osteogenic capacity.
- autograft i.e. the patients own bone, since this is totally biocompatible, is not subject to an immune response or disease transmission and has good osteogenic capacity.
- its source is limited, it requires a second surgical procedure for harvest and there are often donor site morbidity problems.
- Allograft bone is usually considered an acceptable alternative since it is more readily available and has a reasonable level of efficacy. However, it has the potential for disease transmission and since it is ‘foreign’ tissue there is the potential for immunological reactions. In addition, it is a material variable in its properties, due to donor source (often elderly people with osteoporotic bones) and processing variability. This makes prediction of clinical outcome difficult when allograft is used. Delayed healing is a frequent complication.
- a bone implant composition comprising calcium sulphate and slowly soluble sources of calcium, orthophosphate and hydroxyl ions.
- the source of the ions is preferably provided by compounds which are slowly soluble in water, and preferably compounds where the water solubility at room temperature is less than 5 g per litre, desirably less than 1 g per litre, and more desirably less than 0.1 g per litre.
- the source of the calcium ions may be the calcium sulphate alone, or may be provided by one or more of: calcium carbonate, calcium phosphate, calcium oxide, calcium fluoride, calcium citrate, calcium stearate, or dolomite.
- the calcium sulphate may be in the form of dihydrate, hemi-hydrate, soluble anhydrite or insoluble anhydrite.
- the ratio of calcium sulphate to all other compounds in the composition is preferably between 0.2 and 2 parts by weight.
- the composition may also comprise a medicament, and desirably in an effective therapeutic amount.
- the medicament may comprise any of: an antibiotic, an anti-cancer agent, or bone morphogenic protein.
- the source of orthophosphate ions may be one or more of: hydroxyapatite, alpha tricalcium phosphate, beta tricalcium phosphate, dicalcium phosphate, tetracalcium phosphate or magnesium orthophosphate.
- the source of orthophosphate ions may be in the form of a micro-porous granular solid.
- the granules may have a particle size in the range 0.2-5.00 mm.
- the source of orthophosphate may be in the form of a micro-porous granular solid component.
- the source of the hydroxyl ions may be one or more of: calcium oxide, insoluble anhydrite, calcium hydroxide, magnesium oxide, magnesium hydroxide, zinc oxide, zinc hydroxide, or basic magnesium carbonate.
- the ratio of basicity to orthophosphate is preferably between 0.0 and 1.0 molar.
- the composition may be in the form of a powder which can be mixed with water or an aqueous solution to form a usable paste.
- the composition may be in the form of granules or pellets.
- the composition may be formed into pellets using a tablet press.
- the invention also provides a method of forming a bone graft, the method comprising using a bone implant composition according to any of the preceding ten paragraphs.
- the composition When in powder form the composition may be mixed with water or an aqueous solution to form a putty or paste prior to application.
- the putty or paste may be applied to a surgical site by a suitable applicator such as a syringe.
- the putty or paste may be applied to a mould and allowed to set prior to presentation to the surgical site.
- composition is in the form of granules or pellets
- the granules or pellets can be packed into a bone cavity.
- a powdered mixture was prepared according to the following composition:—
- the beta tricalcium phosphate particles have a size of 250-500 microns.
- a powdered mixture was prepared according to the following composition:—
- beta tricalcium phosphate granules with a particle size of 1-2 mm diameter.
- the mixture was pressed into pellets 3 mm diameter by 2.5 mm deep using a tablet press.
- the pellets were used to fill a bone cavity.
- a powdered mixture was prepared according to the following composition:—
- a powdered mixture was prepared according to the following composition:—
- the beta tricalcium phosphate particles have a size range of 1-2 mm.
- the mixture was blended with 9.5 ml of water and compacted into 6 mm diameter cylindrical moulds where it was allowed to set. The set pellets were removed from the moulds and allowed to dry. These were used to fill a bone cavity.
- a powdered mixture was prepared according to the previous example (Example 4), but including 5% by weight of the antibiotic gentamycin which was added to the powdered mix prior to moulding.
- the composition provides a source of ions which precipitate in vivo to provide a poorly crystalline, substituted apatite which closely mimics the natural mineral phase of bone, in contrast to other presently available synthetic bone graft substitutes. Also, the reaction occurs over a time frame commensurate with the body's ability to regenerate new healthy bone. This precipitated hydroxyapatite is amenable to osteoclastic resorption.
- the calcium sulphate phase initially present resorbs by a simple dissolution mechanism over a period of a few weeks to provide a macroporous structure amenable to vascularisation and invasion by new bony tissue. The calcium sulphate forms a micro-porous barrier which prevents intrusion of unwanted soft tissue (cells) in the immediate post implantation period.
- the source of ortho phosphate is preferably a micro-porous granular solid, with a mincee size of 0.2-5 mm. This size range provides for an intergranule pore size of 100-200 microns which is necessary for cell infiltration and vascularization to stimulate new bone in-growth.
- the calcium ions may be obtained from the calcium sulphate alone, or may also be obtained from calcium stearate as in Example 2, or other calcium compounds such as calcium carbonate, calcium phosphate, calcium oxide, calcium fluoride, calcium citrate or dolomite.
- the orthophosphate ions may be provided by beta tricalcium phosphate, these ions may be provided by hydroxyapatite, alpha tricalcium phosphate, dicalcium phosphate, tetracalcium phosphate or magnesium orthophosphate.
- the source of hydroxyl ions is magnesium oxide, and also zinc oxide in Example 3. These ions may though additionally or as an alternative be obtained from calcium oxide, insoluble anhydrite, calcium hydroxide, magnesium hydroxide, zinc hydroxide or basic magnesium carbonate. As illustrated in the Examples, the calcium sulphate may be in one or more of the following forms:— alpha hemihydrate, beta hemihydrate, soluble anhydrite, insoluble anhydrite or dihydrate.
- composition may comprise a medicament in an effective therapeutic amount, which medicament may comprise an antibiotic, an anti-cancer agent, or bone morphogenic protein.
Abstract
A bone implant composition, the composition comprising calcium sulphate and slowly soluble sources of calcium, orthophosphate and hydroxyl ions. The composition may be provided in powder or granulated form.
Description
- This invention concerns a bone implant composition, and a method of forming a bone graft.
- In orthopaedic and dental surgical applications there is a great need for biocompatible and bioresorbable implant material which can be conveniently and effectively used as a bone substitute. This includes bone lost due to periodontal disease, ridge augmentation, sinus elevation, bone defects or cavities due to trauma, disease or surgery and spinal fusions. Following implantation the bone substitute is ideally resorbed in a time frame which is consistent with its replacement by new vital bone.
- The bone graft material of preferred choice is autograft, i.e. the patients own bone, since this is totally biocompatible, is not subject to an immune response or disease transmission and has good osteogenic capacity. However, its source is limited, it requires a second surgical procedure for harvest and there are often donor site morbidity problems.
- Allograft bone is usually considered an acceptable alternative since it is more readily available and has a reasonable level of efficacy. However, it has the potential for disease transmission and since it is ‘foreign’ tissue there is the potential for immunological reactions. In addition, it is a material variable in its properties, due to donor source (often elderly people with osteoporotic bones) and processing variability. This makes prediction of clinical outcome difficult when allograft is used. Delayed healing is a frequent complication.
- According to the present invention there is provided a bone implant composition, the composition comprising calcium sulphate and slowly soluble sources of calcium, orthophosphate and hydroxyl ions.
- The source of the ions is preferably provided by compounds which are slowly soluble in water, and preferably compounds where the water solubility at room temperature is less than 5 g per litre, desirably less than 1 g per litre, and more desirably less than 0.1 g per litre.
- The source of the calcium ions may be the calcium sulphate alone, or may be provided by one or more of: calcium carbonate, calcium phosphate, calcium oxide, calcium fluoride, calcium citrate, calcium stearate, or dolomite.
- The calcium sulphate may be in the form of dihydrate, hemi-hydrate, soluble anhydrite or insoluble anhydrite. The ratio of calcium sulphate to all other compounds in the composition is preferably between 0.2 and 2 parts by weight.
- The composition may also comprise a medicament, and desirably in an effective therapeutic amount. The medicament may comprise any of: an antibiotic, an anti-cancer agent, or bone morphogenic protein.
- The source of orthophosphate ions may be one or more of: hydroxyapatite, alpha tricalcium phosphate, beta tricalcium phosphate, dicalcium phosphate, tetracalcium phosphate or magnesium orthophosphate. The source of orthophosphate ions may be in the form of a micro-porous granular solid. The granules may have a particle size in the range 0.2-5.00 mm. The source of orthophosphate may be in the form of a micro-porous granular solid component.
- The source of the hydroxyl ions may be one or more of: calcium oxide, insoluble anhydrite, calcium hydroxide, magnesium oxide, magnesium hydroxide, zinc oxide, zinc hydroxide, or basic magnesium carbonate.
- In the composition the ratio of basicity to orthophosphate is preferably between 0.0 and 1.0 molar.
- The composition may be in the form of a powder which can be mixed with water or an aqueous solution to form a usable paste.
- Alternatively, the composition may be in the form of granules or pellets. The composition may be formed into pellets using a tablet press.
- The invention also provides a method of forming a bone graft, the method comprising using a bone implant composition according to any of the preceding ten paragraphs.
- When in powder form the composition may be mixed with water or an aqueous solution to form a putty or paste prior to application. The putty or paste may be applied to a surgical site by a suitable applicator such as a syringe. Alternatively the putty or paste may be applied to a mould and allowed to set prior to presentation to the surgical site.
- Where the composition is in the form of granules or pellets, the granules or pellets can be packed into a bone cavity.
- Embodiments of the present invention will now be described by way of example only.
- A powdered mixture was prepared according to the following composition:—
- 1.25 g beta tricalcium phosphate
- 0.63 g calcium sulphate alpha hemihydrate
- 0.05 g magnesium oxide
- The beta tricalcium phosphate particles have a size of 250-500 microns.
- The mixture was blended with 0.85 ml of a 1% potassium sulphate solution to give a paste which was used to fill a periodontal pocket.
- A powdered mixture was prepared according to the following composition:—
- 35.0 g beta tricalcium phosphate granules with a particle size of 1-2 mm diameter.
- 17.5 g calcium sulphate dihydrate
- 2.2 g magnesium oxide
- 0.80 g calcium stearate
- The mixture was pressed into pellets 3 mm diameter by 2.5 mm deep using a tablet press. The pellets were used to fill a bone cavity.
- A powdered mixture was prepared according to the following composition:—
- 35.0 g alpha tricalcium phosphate
- 14.0 g anhydrous calcium sulphate-insoluble form
- 10.0 g basic magnesium carbonate
- 0.1 g zinc oxide
- The mixture was pressed into pellets using a tablet press.
- A powdered mixture was prepared according to the following composition:—
- 10.0 g beta tricalcium phosphate particles
- 5.0 g calcium sulphate alpha hemihydrate powder
- 0.5 g magnesium oxide
- The beta tricalcium phosphate particles have a size range of 1-2 mm.
- The mixture was blended with 9.5 ml of water and compacted into 6 mm diameter cylindrical moulds where it was allowed to set. The set pellets were removed from the moulds and allowed to dry. These were used to fill a bone cavity.
- A powdered mixture was prepared according to the previous example (Example 4), but including 5% by weight of the antibiotic gentamycin which was added to the powdered mix prior to moulding.
- There is thus described a bone implant composition and a method of using same which provides for considerable advantages. The composition is based upon the following chemical equation:—
- 10Ca2++6PO4 3−+2OH−=Ca10(PO4)6(OH)2
- The composition provides a source of ions which precipitate in vivo to provide a poorly crystalline, substituted apatite which closely mimics the natural mineral phase of bone, in contrast to other presently available synthetic bone graft substitutes. Also, the reaction occurs over a time frame commensurate with the body's ability to regenerate new healthy bone. This precipitated hydroxyapatite is amenable to osteoclastic resorption. The calcium sulphate phase initially present resorbs by a simple dissolution mechanism over a period of a few weeks to provide a macroporous structure amenable to vascularisation and invasion by new bony tissue. The calcium sulphate forms a micro-porous barrier which prevents intrusion of unwanted soft tissue (cells) in the immediate post implantation period.
- The source of ortho phosphate is preferably a micro-porous granular solid, with a partide size of 0.2-5 mm. This size range provides for an intergranule pore size of 100-200 microns which is necessary for cell infiltration and vascularization to stimulate new bone in-growth.
- Various modifications may be made without departing from the scope of the invention. The calcium ions may be obtained from the calcium sulphate alone, or may also be obtained from calcium stearate as in Example 2, or other calcium compounds such as calcium carbonate, calcium phosphate, calcium oxide, calcium fluoride, calcium citrate or dolomite. In addition or as an alternative to the orthophosphate ions being provided by beta tricalcium phosphate, these ions may be provided by hydroxyapatite, alpha tricalcium phosphate, dicalcium phosphate, tetracalcium phosphate or magnesium orthophosphate.
- In the examples the source of hydroxyl ions is magnesium oxide, and also zinc oxide in Example 3. These ions may though additionally or as an alternative be obtained from calcium oxide, insoluble anhydrite, calcium hydroxide, magnesium hydroxide, zinc hydroxide or basic magnesium carbonate. As illustrated in the Examples, the calcium sulphate may be in one or more of the following forms:— alpha hemihydrate, beta hemihydrate, soluble anhydrite, insoluble anhydrite or dihydrate.
- The composition may comprise a medicament in an effective therapeutic amount, which medicament may comprise an antibiotic, an anti-cancer agent, or bone morphogenic protein.
- Whilst endeavouring in the foregoing specification to draw attention to those features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature or combination of features hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.
Claims (26)
1. A bone implant composition characterised in that the composition comprises calcium sulphate and slowly soluble sources of calcium, orthophosphate and hydroxyl ions.
2. A composition according to claim 1 , characterised in that the source of the ions is provided by compounds which are slowly soluble in water.
3. A composition according to claim 2 , characterised in that water solubility of the compounds at room temperature is less than 5 g per litre.
4. A composition according to claim 3 , characterised in that water solubility of the compounds at room temperature is less than 1 g per litre.
5. A composition according to claim 4 , characterised in that water solubility of the compounds at room temperature is less than 0.1 g per litre.
6. A composition according to any of the preceding claims, characterised in that the source of the calcium ions is the calcium sulphate alone.
7. A composition according to any of claims 1 to 5 , characterised in that the source of the calcium ions is provided by one or more of: calcium carbonate, calcium phosphate, calcium oxide, calcium fluoride, calcium citrate, calcium stearate, or dolomite.
8. A composition according to any of the preceding claims, characterised in that the calcium sulphate is in the form of dehydrate, hemi-hydrate, soluble anhydrite or insoluble anhydrite.
9. A composition according to any of the preceding claims, characterised in that the ratio of calcium sulphate to all other compounds in the composition is between 0.2 and 2 parts by weight.
10. A composition according to any of the preceding claims, characterised in that the composition comprises a medicament.
11. A composition according to claim 10 , characterised in that the medicament is in an effective therapeutic amount.
12. A composition according to claim 10 or claim 11 , characterised in that the medicament comprises any of: an antibiotic, an anti-cancer agent, or bone morphogenic protein.
13. A composition according to any of the preceding claims, characterised in that the source of orthophosphate ions is one or more of: hydroxyapatite, alpha tricalcium phosphate, beta tricalcium phosphate, dicalcium phosphate, tetracalcium phosphate or magnesium orthophosphate.
14. A composition according to any of the preceding claims, characterised in that the source of orthophosphate ions is in the form of a micro-porous granular solid.
15. A composition according to claim 14 , characterised in that the granules have a particle size in the range 0.2-5.00 mm.
16. A composition according to any of the preceding claims, characterised in that the source of the hydroxyl ions may be one or more of: calcium oxide, insoluble anhydrite, calcium hydroxide, magnesium oxide, magnesium hydroxide, zinc oxide, zinc hydroxide, or basic magnesium carbonate.
17. A composition according to any of the preceding claims, characterised in that in the composition the ratio of basicity to orthophosphate is between 0.0 and 1.0 molar.
18. A composition according to any of the preceding claims, characterised in that the composition is in the form of a powder which can be mixed with water or an aqueous solution to form a usable paste.
19. A composition according to any of claims 1 to 17 , characterised in that the composition is in the form of granules or pellets.
20. A composition according to claim 19 , characterised in that the composition is formed into pellets using a tablet press.
21. A method of forming a bone graft, characterised in that the method comprises using a bone implant composition according to any of the preceding claims.
22. A method according to claim 21 when dependent on claim 18 , characterised in that when in powder form the composition is mixed with water or an aqueous solution to form a putty or paste prior to application.
23. A method according to claim 22 , characterised in that the putty or paste is applied to a surgical site by a suitable applicator such as a syringe.
24. A method according to claim 22 , characterised in that the putty or paste is applied to a mould and allowed to set prior to presentation to the surgical site.
25. A method according to claim 21 when dependent on claim 19 or claim 20 , characterised in that when the composition is in the form of granules or pellets, the granules or pellets can be packed into a bone cavity.
26. Any novel subject matter or combination including novel subject matter disclosed herein, whether or not within the scope of or relating to the same invention as any of the preceding claims.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/356,357 US8632796B2 (en) | 2001-05-02 | 2009-01-20 | Calcium phosphate/sulfate-based bone implant composition |
US13/241,999 US8496955B2 (en) | 2001-05-02 | 2011-09-23 | Calcium phosphate/sulfate-based bone implant composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0110726.7A GB0110726D0 (en) | 2001-05-02 | 2001-05-02 | Bone implant composition |
GB0110726.7 | 2001-05-02 | ||
PCT/GB2002/001986 WO2002087649A1 (en) | 2001-05-02 | 2002-05-01 | Calcium phosphate/sulphate-based bone implant composition |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/001986 A-371-Of-International WO2002087649A1 (en) | 2001-05-02 | 2002-05-01 | Calcium phosphate/sulphate-based bone implant composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/356,357 Division US8632796B2 (en) | 2001-05-02 | 2009-01-20 | Calcium phosphate/sulfate-based bone implant composition |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040151751A1 true US20040151751A1 (en) | 2004-08-05 |
Family
ID=9913856
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/476,242 Abandoned US20040151751A1 (en) | 2001-05-02 | 2002-05-01 | Calcium phosphate/sulphate-based bone implant composition |
US12/356,357 Expired - Lifetime US8632796B2 (en) | 2001-05-02 | 2009-01-20 | Calcium phosphate/sulfate-based bone implant composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/356,357 Expired - Lifetime US8632796B2 (en) | 2001-05-02 | 2009-01-20 | Calcium phosphate/sulfate-based bone implant composition |
Country Status (9)
Country | Link |
---|---|
US (2) | US20040151751A1 (en) |
EP (1) | EP1390086B1 (en) |
JP (1) | JP2004528904A (en) |
CN (1) | CN1265846C (en) |
AT (1) | ATE285801T1 (en) |
DE (1) | DE60202461T2 (en) |
ES (1) | ES2235026T3 (en) |
GB (1) | GB0110726D0 (en) |
WO (1) | WO2002087649A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030161858A1 (en) * | 2000-04-11 | 2003-08-28 | Lars Lidgren | Injectable bone mineral substitute material |
US20040048947A1 (en) * | 2000-07-17 | 2004-03-11 | Lars Lidgren | Composition for an injectable bone mineral substitute material |
US20050119746A1 (en) * | 2001-12-20 | 2005-06-02 | Lars Lidgren | Bone mineral substitute |
US20070041906A1 (en) * | 2003-03-05 | 2007-02-22 | Lars Lidgren | Bone substitute composition |
US20070161943A1 (en) * | 2003-11-11 | 2007-07-12 | Lars Lidgren | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US20070217282A1 (en) * | 2004-06-22 | 2007-09-20 | Bone Support Ab | Device for Producing a Hardenable Mass |
KR100759718B1 (en) | 2004-12-21 | 2007-10-04 | 요업기술원 | Porous calcium phosphates using a hydrothermal hot pressing method and Preparation thereof |
US20080020349A1 (en) * | 2005-02-24 | 2008-01-24 | Roland Dricot | Bone implant |
US20090022811A1 (en) * | 2007-03-07 | 2009-01-22 | Legeros Racquel Z | Mineralized guided bone regeneration membranes and methods of making the same |
US20110152195A1 (en) * | 2009-12-18 | 2011-06-23 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
US8496955B2 (en) | 2001-05-02 | 2013-07-30 | Biocomposites Limited | Calcium phosphate/sulfate-based bone implant composition |
US20140314849A1 (en) * | 2013-04-18 | 2014-10-23 | Novagenit S.R.L. | Method for preparing biocompatible and biodegradable biomaterials based on collagen and granules of hydroxyapatite/beta-tricalcium phosphate for use in surgery, and biomaterials thus obtained |
US20140335197A1 (en) * | 2013-05-10 | 2014-11-13 | Reed A. Ayers | Combustion synthesis of calcium phosphate constructs and powders doped with atoms, molecules, ions, or compounds |
US9127166B2 (en) | 2009-05-22 | 2015-09-08 | Bpb Limited | Calcium sulphate-based products having enhanced water resistance |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US10182973B2 (en) | 2010-11-10 | 2019-01-22 | Stryker European Holdings I, Llc | Polymeric bone foam composition and method |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
CN112043862A (en) * | 2020-09-14 | 2020-12-08 | 香港大学深圳医院 | Magnesium slow-release bone cement with self-curing function and preparation method thereof |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL372114A1 (en) * | 2002-06-19 | 2005-07-11 | Dr.H.C.Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
EP1680089B1 (en) | 2003-10-22 | 2013-09-11 | Lidds AB | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
ES2402651T3 (en) | 2005-09-09 | 2013-05-07 | Agnovos Healthcare, Llc | Cement substitute for bone graft of composite material and articles produced from it |
US8685432B2 (en) | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
IL255113B (en) * | 2009-05-06 | 2022-09-01 | Laboratory Skin Care Inc | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
ES2816576T3 (en) * | 2009-07-16 | 2021-04-05 | Univ Missouri | Trace element scaffolds for tissue regeneration in mammals |
PL3289886T3 (en) * | 2010-01-12 | 2019-09-30 | Mars, Incorporated | Multi-component pet food and method of manufacturing solid component |
US20120028204A1 (en) * | 2010-08-02 | 2012-02-02 | Lazarou Spiros A | Correction of alveolar cleft with calcium-based bone graft materials |
WO2012054009A1 (en) * | 2010-10-19 | 2012-04-26 | Jiin-Huey Chern Lin | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
US9889235B2 (en) | 2013-02-05 | 2018-02-13 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
EP3964216B1 (en) * | 2018-04-23 | 2024-03-06 | Moroxite T AB | Novel treatment approach by targeted delivery of bioactive molecules bio modulated ceramics |
CN109549954B (en) * | 2018-12-13 | 2020-09-04 | 中国科学院深圳先进技术研究院 | Phosphorus-based material preparation and preparation method and application thereof |
CN110558311A (en) * | 2019-09-17 | 2019-12-13 | 海南医学院第一附属医院 | medical material for preserving isolated bone in trauma and war injury and preparation method thereof |
CN110496245A (en) * | 2019-09-17 | 2019-11-26 | 彭磊 | A kind of medical material and preparation method thereof for treating osteomyelitis |
CN114375968B (en) * | 2022-01-24 | 2023-09-26 | 河南科技大学 | Self-curing nontoxic antibacterial material and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778471A (en) * | 1986-11-19 | 1988-10-18 | University Of Dayton | Zcap ceramics |
US5824087A (en) * | 1994-04-11 | 1998-10-20 | Aberdeen University And Plasma Biotal Limited | Bone regeneration |
US20010032022A1 (en) * | 1998-11-06 | 2001-10-18 | Ricci John L. | Surgical implant system,article and kit |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2529613B2 (en) | 1990-03-09 | 1996-08-28 | 学校法人松本歯科大学 | Curable composition |
US5149368A (en) * | 1991-01-10 | 1992-09-22 | Liu Sung Tsuen | Resorbable bioactive calcium phosphate cement |
CA2119090A1 (en) | 1993-03-26 | 1994-09-27 | Wayne R. Gombotz | Compositions for controlled release of biologically active tgf-.beta. |
JPH078548A (en) | 1993-06-24 | 1995-01-13 | Mitsui Toatsu Chem Inc | Hardenable powder for living body |
AU3795395A (en) * | 1994-11-30 | 1996-06-06 | Ethicon Inc. | Hard tissue bone cements and substitutes |
DE19853832A1 (en) | 1998-11-21 | 2000-05-25 | Merck Patent Gmbh | Calcium phosphate cements containing polyalkenoic acids |
-
2001
- 2001-05-02 GB GBGB0110726.7A patent/GB0110726D0/en not_active Ceased
-
2002
- 2002-05-01 EP EP02720293A patent/EP1390086B1/en not_active Expired - Lifetime
- 2002-05-01 DE DE60202461T patent/DE60202461T2/en not_active Expired - Lifetime
- 2002-05-01 CN CNB028091949A patent/CN1265846C/en not_active Expired - Lifetime
- 2002-05-01 AT AT02720293T patent/ATE285801T1/en not_active IP Right Cessation
- 2002-05-01 WO PCT/GB2002/001986 patent/WO2002087649A1/en active IP Right Grant
- 2002-05-01 JP JP2002584991A patent/JP2004528904A/en active Pending
- 2002-05-01 ES ES02720293T patent/ES2235026T3/en not_active Expired - Lifetime
- 2002-05-01 US US10/476,242 patent/US20040151751A1/en not_active Abandoned
-
2009
- 2009-01-20 US US12/356,357 patent/US8632796B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778471A (en) * | 1986-11-19 | 1988-10-18 | University Of Dayton | Zcap ceramics |
US5824087A (en) * | 1994-04-11 | 1998-10-20 | Aberdeen University And Plasma Biotal Limited | Bone regeneration |
US20010032022A1 (en) * | 1998-11-06 | 2001-10-18 | Ricci John L. | Surgical implant system,article and kit |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7972630B2 (en) | 2000-04-11 | 2011-07-05 | Bone Support Ab | Injectable bone mineral substitute material |
US20030161858A1 (en) * | 2000-04-11 | 2003-08-28 | Lars Lidgren | Injectable bone mineral substitute material |
US20040048947A1 (en) * | 2000-07-17 | 2004-03-11 | Lars Lidgren | Composition for an injectable bone mineral substitute material |
US20080286331A1 (en) * | 2000-07-17 | 2008-11-20 | Bone Support Ab | Composition for an injectable bone mineral substitute material |
US7417077B2 (en) | 2000-07-17 | 2008-08-26 | Bone Support Ab | Composition for an injectable bone mineral substitute material |
US8496955B2 (en) | 2001-05-02 | 2013-07-30 | Biocomposites Limited | Calcium phosphate/sulfate-based bone implant composition |
US8586101B2 (en) | 2001-12-20 | 2013-11-19 | Bone Support Ab | Bioresorbable bone mineral substitute comprising water-soluble X-ray contrast agent |
US20050119746A1 (en) * | 2001-12-20 | 2005-06-02 | Lars Lidgren | Bone mineral substitute |
US8420127B2 (en) | 2003-03-05 | 2013-04-16 | Bone Support Ab | Bone substitute composition |
US20070041906A1 (en) * | 2003-03-05 | 2007-02-22 | Lars Lidgren | Bone substitute composition |
US20070161943A1 (en) * | 2003-11-11 | 2007-07-12 | Lars Lidgren | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US20110087161A1 (en) * | 2003-11-11 | 2011-04-14 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US7935121B2 (en) | 2003-11-11 | 2011-05-03 | Bone Support Ab | Device for providing spongy bone with bone substitute and/or bone reinforcing material, bone substitute and/or bone reinforcing material and method |
US8297831B2 (en) | 2004-06-22 | 2012-10-30 | Bone Support Ab | Device for producing a hardenable mass |
US7938572B2 (en) | 2004-06-22 | 2011-05-10 | Bone Support Ab | Device for producing a hardenable mass |
US20070217282A1 (en) * | 2004-06-22 | 2007-09-20 | Bone Support Ab | Device for Producing a Hardenable Mass |
US8662737B2 (en) | 2004-06-22 | 2014-03-04 | Bone Support Ab | Device for producing a hardenable mass |
KR100759718B1 (en) | 2004-12-21 | 2007-10-04 | 요업기술원 | Porous calcium phosphates using a hydrothermal hot pressing method and Preparation thereof |
US20080020349A1 (en) * | 2005-02-24 | 2008-01-24 | Roland Dricot | Bone implant |
US20090022811A1 (en) * | 2007-03-07 | 2009-01-22 | Legeros Racquel Z | Mineralized guided bone regeneration membranes and methods of making the same |
US9127166B2 (en) | 2009-05-22 | 2015-09-08 | Bpb Limited | Calcium sulphate-based products having enhanced water resistance |
US8481065B2 (en) | 2009-12-18 | 2013-07-09 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
US8722073B2 (en) | 2009-12-18 | 2014-05-13 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
US20110152195A1 (en) * | 2009-12-18 | 2011-06-23 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US10182973B2 (en) | 2010-11-10 | 2019-01-22 | Stryker European Holdings I, Llc | Polymeric bone foam composition and method |
US11185475B2 (en) | 2010-11-10 | 2021-11-30 | Stryker European Operations Holdings Llc | Polymeric bone foam composition and method |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
US10994998B2 (en) | 2013-02-20 | 2021-05-04 | Bone Support Ab | Setting of hardenable bone substitute |
US9415091B2 (en) * | 2013-04-18 | 2016-08-16 | Novagenit S.R.L. | Method for preparing biocompatible and biodegradable biomaterials based on collagen and granules of hydroxyapatite/β-tricalcium phosphate for use in surgery, and biomaterials thus obtained |
US20140314849A1 (en) * | 2013-04-18 | 2014-10-23 | Novagenit S.R.L. | Method for preparing biocompatible and biodegradable biomaterials based on collagen and granules of hydroxyapatite/beta-tricalcium phosphate for use in surgery, and biomaterials thus obtained |
US20140335197A1 (en) * | 2013-05-10 | 2014-11-13 | Reed A. Ayers | Combustion synthesis of calcium phosphate constructs and powders doped with atoms, molecules, ions, or compounds |
US10118827B2 (en) * | 2013-05-10 | 2018-11-06 | Reed A. Ayers | Combustion synthesis of calcium phosphate constructs and powders doped with atoms, molecules, ions, or compounds |
CN112043862A (en) * | 2020-09-14 | 2020-12-08 | 香港大学深圳医院 | Magnesium slow-release bone cement with self-curing function and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2235026T3 (en) | 2005-07-01 |
WO2002087649A1 (en) | 2002-11-07 |
JP2004528904A (en) | 2004-09-24 |
GB0110726D0 (en) | 2001-06-27 |
US8632796B2 (en) | 2014-01-21 |
ATE285801T1 (en) | 2005-01-15 |
EP1390086A1 (en) | 2004-02-25 |
DE60202461T2 (en) | 2005-12-29 |
CN1535165A (en) | 2004-10-06 |
EP1390086B1 (en) | 2004-12-29 |
US20090124536A1 (en) | 2009-05-14 |
CN1265846C (en) | 2006-07-26 |
DE60202461D1 (en) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8632796B2 (en) | Calcium phosphate/sulfate-based bone implant composition | |
US5149368A (en) | Resorbable bioactive calcium phosphate cement | |
Khan et al. | Bioactive behavior of silicon substituted calcium phosphate based bioceramics for bone regeneration | |
JP5153046B2 (en) | Cement preparation and method of use thereof | |
AU2001271209B2 (en) | A composition for an injectable bone mineral substitute material | |
Hughes et al. | Inorganic cements for biomedical application: calcium phosphate, calcium sulphate and calcium silicate | |
Garrido et al. | Biphasic calcium phosphate bioceramics for orthopaedic reconstructions: clinical outcomes | |
US6706273B1 (en) | Composition for implantation into the human and animal body | |
CA2487994C (en) | Hydraulic cement based on calcium phosphate for surgical use | |
JP5323354B2 (en) | Multipurpose biomaterial composition | |
US20090318982A1 (en) | Methods of injecting calcium based neutral and bioresorbable bone grafts | |
JPH07206489A (en) | Calcium phosphate cement composition, its preparation and its method of application | |
US8496955B2 (en) | Calcium phosphate/sulfate-based bone implant composition | |
Atayde et al. | Morphology effect of bioglass‐reinforced hydroxyapatite (Bonelike®) on osteoregeneration | |
WO2006076426A2 (en) | Multi-purpose bio-material composition | |
LeGeros et al. | Bioactive bioceramics | |
Daculsi et al. | The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering | |
Mansour et al. | Alveolar bone grafting: Rationale and clinical applications | |
Niwa et al. | Injectable calcium phosphate cements for repair of bone defects | |
Tofighi et al. | New generation of synthetic, bioresorbable and injectable calcium phosphate bone substitute materials: Alpha-bsm®, Beta-bsmTM and Gamma-bsmTM | |
Katthagen et al. | Bone-Replacement Materials | |
Biomate’riaux | THE IVIICRO IVIACROPOROUS BIPHASIC CALCIUIVI PHOSPHATE CONCEPT FOR BONE RECONSTRUCTION AND TISSUE ENGINEERING | |
Passuti et al. | Bone substitutes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOCOMPOSITES LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COOPER, JOHN JOSEPH;REEL/FRAME:015137/0166 Effective date: 20031106 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |